Bone Marrow Transplantation最新文献

筛选
英文 中文
The EASIX score as a predictor of sinusoidal obstruction syndrome and nonrelapse mortality in paediatric patients receiving allogeneic haematopoietic stem cell transplantation. EASIX评分作为接受同种异体造血干细胞移植的儿科患者鼻窦阻塞综合征和非复发死亡率的预测因子。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-12-10 DOI: 10.1038/s41409-024-02489-8
Edoardo Muratore, Giacomo Gambuti, Davide Leardini, Francesco Baccelli, Francesco Venturelli, Leyna Larcinese, Francesca Gottardi, Antonia Di Battista, Tamara Belotti, Arcangelo Prete, Riccardo Masetti
{"title":"The EASIX score as a predictor of sinusoidal obstruction syndrome and nonrelapse mortality in paediatric patients receiving allogeneic haematopoietic stem cell transplantation.","authors":"Edoardo Muratore, Giacomo Gambuti, Davide Leardini, Francesco Baccelli, Francesco Venturelli, Leyna Larcinese, Francesca Gottardi, Antonia Di Battista, Tamara Belotti, Arcangelo Prete, Riccardo Masetti","doi":"10.1038/s41409-024-02489-8","DOIUrl":"https://doi.org/10.1038/s41409-024-02489-8","url":null,"abstract":"<p><p>The endothelial activation and stress index (EASIX) score, calculated as [lactate dehydrogenase (LDH; U/L) × serum creatinine (mg/dL)]/platelets (10e9/L)], has been shown to be predictive of nonrelapse mortality (NRM) and endothelial complications in adults receiving allogeneic stem cell transplantation (allo-HSCT); however, definitive results are lacking for children. We retrospectively evaluated consecutive paediatric allo-HSCT recipients and calculated the log2 EASIX score every day from admission to day +35. In 167 allo-HSCT recipients, the EASIX score increased from before conditioning (-0.79) to a maximum score on day +20 (2.23). In multivariate analysis, the EASIX score at day +7 was an independent predictor of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) (OR 1.52; 95% CI, 1.08-2.13; p = 0.017) and NRM (OR 1.68; 95% CI 1.16-2.42; p = 0.006). At several time points between day +0 and day +14, the EASIX score was independently associated with NRM, with the strongest predictive power being observed on day +12 (OR 3.05; 95% CI, 1.53-6.10; p = 0.002). Age correlated linearly with the EASIX score at all analysed time points, but score prediction was confirmed even when age was added to the multivariate model, indicating that age was not a confounding factor in the observed associations. The EASIX score determined shortly after transplantation can be further explored as a predictor of SOS/VOD and NRM in paediatric allo-HSCT recipients.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142805866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guinness 0.0: a miracle! 吉尼斯0.0:奇迹!
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-12-09 DOI: 10.1038/s41409-024-02492-z
Shaun R McCann
{"title":"Guinness 0.0: a miracle!","authors":"Shaun R McCann","doi":"10.1038/s41409-024-02492-z","DOIUrl":"https://doi.org/10.1038/s41409-024-02492-z","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma. 自体干细胞单次与串联移植治疗新诊断的多发性骨髓瘤。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-12-05 DOI: 10.1038/s41409-024-02490-1
Nora Grieb, Alexander Oeser, Maximilian Ferle, Franziska Hanke, Sarah Flossdorf, Sandra Sauer, Hartmut Goldschmidt, Carsten Müller-Tidow, Hans-Jürgen Salwender, Roland Fenk, Monika Engelhardt, Robert Zeiser, Vladan Vucinic, Georg-Nikolaus Franke, Igor Wolfgang Blau, Daniel Teschner, Hermann Einsele, Christoph Kimmich, Miriam Kull, Britta Besemer, Nico Gagelmann, Nicolaus Kröger, Thomas Neumuth, Uwe Platzbecker, Maximilian Merz
{"title":"Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma.","authors":"Nora Grieb, Alexander Oeser, Maximilian Ferle, Franziska Hanke, Sarah Flossdorf, Sandra Sauer, Hartmut Goldschmidt, Carsten Müller-Tidow, Hans-Jürgen Salwender, Roland Fenk, Monika Engelhardt, Robert Zeiser, Vladan Vucinic, Georg-Nikolaus Franke, Igor Wolfgang Blau, Daniel Teschner, Hermann Einsele, Christoph Kimmich, Miriam Kull, Britta Besemer, Nico Gagelmann, Nicolaus Kröger, Thomas Neumuth, Uwe Platzbecker, Maximilian Merz","doi":"10.1038/s41409-024-02490-1","DOIUrl":"https://doi.org/10.1038/s41409-024-02490-1","url":null,"abstract":"<p><p>Identifying patients who may benefit from autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma is crucial, especially in the era of effective induction and consolidation strategies. We analyzed data from 12763 patients enrolled in the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST), distinguishing those who underwent single (n = 8736) or tandem ASCT (n = 4027) from 1998 to 2021. Our findings show that the median age at first ASCT increased over time, while the use of tandem ASCT declined. The shift in treatment practices coincided with higher rates of complete response (CR) post-induction therapy. Significantly improved overall survival and event-free survival over time were observed across all age groups, especially in older patients, but not in patients under 40. Tandem ASCT showed benefits for patients who did not achieve CR after initial ASCT. However, patients with ISS III and renal impairment had poorer outcomes with tandem ASCT. In conclusion, while ASCT remains an important anti-myeloma tool, careful patient selection for tandem ASCT is essential, particularly avoiding its use in patients with ISS III and renal impairment, older age, and those already achieving CR after initial ASCT.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Better pre-transplant treatment options for TP53-mutated MDS: cytoreductive or non-cytoreductive therapy? tp53突变MDS更好的移植前治疗选择:细胞减少治疗还是非细胞减少治疗?
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-12-04 DOI: 10.1038/s41409-024-02486-x
Bingqian Jiang, Tingting Yang, Yanmin Zhao, Yi Luo, Guifang Ouyang, Jian Yu, Yishan Ye, Jianping Lan, Ying Lu, Xiaoyu Lai, Baodong Ye, Yi Chen, Lizhen Liu, Yang Xu, Pengfei Shi, Haowen Xiao, Huixian Hu, Qunyi Guo, Huarui Fu, Xinyu Wang, Jie Sun, Weiyan Zheng, Jingsong He, Yi Zhao, Wenjun Wu, Zhen Cai, Guoqing Wei, He Huang, Jimin Shi
{"title":"Better pre-transplant treatment options for TP53-mutated MDS: cytoreductive or non-cytoreductive therapy?","authors":"Bingqian Jiang, Tingting Yang, Yanmin Zhao, Yi Luo, Guifang Ouyang, Jian Yu, Yishan Ye, Jianping Lan, Ying Lu, Xiaoyu Lai, Baodong Ye, Yi Chen, Lizhen Liu, Yang Xu, Pengfei Shi, Haowen Xiao, Huixian Hu, Qunyi Guo, Huarui Fu, Xinyu Wang, Jie Sun, Weiyan Zheng, Jingsong He, Yi Zhao, Wenjun Wu, Zhen Cai, Guoqing Wei, He Huang, Jimin Shi","doi":"10.1038/s41409-024-02486-x","DOIUrl":"https://doi.org/10.1038/s41409-024-02486-x","url":null,"abstract":"<p><p>Patients with TP53-mutated myelodysplastic neoplasms (MDS) have unfavorable prognoses; the benefit of cytoreductive treatment before hematopoietic stem cell transplantation (HSCT) is debated. We retrospectively analyzed 284 MDS patients undergoing allogeneic HSCT; among which 49 had TP53 mutation, with 38 receiving cytoreduction and 11 treated exclusively with best supportive care (BSC) before transplantation. Regardless of TP53 allelic state, patients with mutated-TP53 had a lower overall survival rate and higher relapse rate than those with wild-type TP53 (P < 0.001, P = 0.002, respectively). Among the TP53-mutated cohort, the 2-year overall survival rate in the cytoreduction group was comparable to that in the BSC group (34.6% vs. 45.5%, P = 0.53), and no other prognostic benefit was observed as well (all P < 0.05). Moreover, no prognostic difference was found among the chemotherapy subgroup, hypomethylating agent subgroup, and BSC subgroup (all P > 0.05). Patients in the pre-HSCT measurable residual disease (MRD) negative subgroup, pre-HSCT MRD-positive subgroup, and BSC subgroup exhibited similar prognoses (all P > 0.05). Multivariate analyses showed that pre-HSCT cytoreduction was not associated with post-transplant survival (all P > 0.05). In conclusion, TP53-mutated MDS patients have poor post-HSCT outcomes; compared to BSC, pre-HSCT cytoreduction doesn't improve prognosis, even in those with MRD negative before transplantation.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emapalumab for the Treatment of Immune-Mediated Graft Failure after HSCT. Emapalumab治疗HSCT后免疫介导的移植物衰竭。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-12-03 DOI: 10.1038/s41409-024-02487-w
Pietro Merli, Sonata Jodele, Eleanor Cook, Kasiani C Myers, Adam Lane, Samppa Ryhänen, Maria Pia Cefalo, Francesco Quagliarella, Stella M Davies, Ashley Teusink-Cross, Paibel Aguayo-Hiraldo, Jessie L Alexander, Paul Szabolcs, Mira Kohorst, Tiziana Corsetti, Franco Locatelli, Anthony Sabulski
{"title":"Emapalumab for the Treatment of Immune-Mediated Graft Failure after HSCT.","authors":"Pietro Merli, Sonata Jodele, Eleanor Cook, Kasiani C Myers, Adam Lane, Samppa Ryhänen, Maria Pia Cefalo, Francesco Quagliarella, Stella M Davies, Ashley Teusink-Cross, Paibel Aguayo-Hiraldo, Jessie L Alexander, Paul Szabolcs, Mira Kohorst, Tiziana Corsetti, Franco Locatelli, Anthony Sabulski","doi":"10.1038/s41409-024-02487-w","DOIUrl":"https://doi.org/10.1038/s41409-024-02487-w","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study. 更正:造血细胞移植后胎盘扩张间充质样细胞(PLX-R18)移植物功能差:一项I期研究。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-12-03 DOI: 10.1038/s41409-024-02469-y
Joseph P McGuirk, Leland Metheny, Luis Pineiro, Mark Litzow, Scott D Rowley, Batia Avni, Roni Tamari, Hillard M Lazarus, Jacob M Rowe, Michal Sheleg, Daniel Rothenstein, Nitsan Halevy, Tsila Zuckerman
{"title":"Correction: Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study.","authors":"Joseph P McGuirk, Leland Metheny, Luis Pineiro, Mark Litzow, Scott D Rowley, Batia Avni, Roni Tamari, Hillard M Lazarus, Jacob M Rowe, Michal Sheleg, Daniel Rothenstein, Nitsan Halevy, Tsila Zuckerman","doi":"10.1038/s41409-024-02469-y","DOIUrl":"https://doi.org/10.1038/s41409-024-02469-y","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and prognostic assessment of chemotherapy-bridged transplantation in pediatric patients with advanced myelodysplastic syndromes. 化疗桥接移植治疗小儿晚期骨髓增生异常综合征的疗效和预后评估。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-12-02 DOI: 10.1038/s41409-024-02488-9
Xingchen Wang, Chenmeng Liu, Yunlong Chen, Yang Wan, Wenbin An, Xiaolan Li, Lipeng Liu, Fang Liu, Li Zhang, Yao Zou, Xiaojuan Chen, Yumei Chen, Ye Guo, Xiaofan Zhu, Wenyu Yang
{"title":"Efficacy and prognostic assessment of chemotherapy-bridged transplantation in pediatric patients with advanced myelodysplastic syndromes.","authors":"Xingchen Wang, Chenmeng Liu, Yunlong Chen, Yang Wan, Wenbin An, Xiaolan Li, Lipeng Liu, Fang Liu, Li Zhang, Yao Zou, Xiaojuan Chen, Yumei Chen, Ye Guo, Xiaofan Zhu, Wenyu Yang","doi":"10.1038/s41409-024-02488-9","DOIUrl":"https://doi.org/10.1038/s41409-024-02488-9","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study. 骨髓肉瘤患者异体造血干细胞移植与强化化疗的结果:一项具有全国代表性的多中心研究。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-12-02 DOI: 10.1038/s41409-024-02485-y
Jie Sun, Yi-Cheng Zhang, Jia Wei, Ya-Jing Xu, Yue Zhang, Yu-Hua Li, An-Qin Wu, Lei Fan, Yu Zhu, Feng-Qi Liu, Zhong-Xing Jiang, Chao Liu, Ming Jiang, Jian-Hua Qu, Peng-Cheng He, Jie Wang, Xiao-Bing Huang, Rong Xiao, Su-Jun Gao, Qiang Guo, San-Bin Wang, Xiao-Ping Li, Sheng-Jin Fan, Li-Li Sun, Lan-Ping Xu, Xiao-Jun Huang, Xiao-Hui Zhang
{"title":"Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study.","authors":"Jie Sun, Yi-Cheng Zhang, Jia Wei, Ya-Jing Xu, Yue Zhang, Yu-Hua Li, An-Qin Wu, Lei Fan, Yu Zhu, Feng-Qi Liu, Zhong-Xing Jiang, Chao Liu, Ming Jiang, Jian-Hua Qu, Peng-Cheng He, Jie Wang, Xiao-Bing Huang, Rong Xiao, Su-Jun Gao, Qiang Guo, San-Bin Wang, Xiao-Ping Li, Sheng-Jin Fan, Li-Li Sun, Lan-Ping Xu, Xiao-Jun Huang, Xiao-Hui Zhang","doi":"10.1038/s41409-024-02485-y","DOIUrl":"https://doi.org/10.1038/s41409-024-02485-y","url":null,"abstract":"<p><p>Myeloid sarcoma (MS) is a rare hematological neoplasm with poor prognosis, posing a significant clinical challenge due to the absence of effective and standardized treatments. We conducted a retrospective analysis of 162 MS patients treated at 12 centers to compare outcomes between intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our analysis revealed that allo-HSCT demonstrated superior overall survival (OS) within the initial 36 months compared to intensive chemotherapy alone (p = 0.037). However, beyond 36 months (36-60 months), a reverse trend was observed (p = 0.056). Subgroup analysis revealed potential benefit for isolated MS patients with allo-HSCT, but not for those with leukemic MS. Additionally, in patients achieving first complete remission (CR1) after induction chemotherapy, allo-HSCT did not significantly improve 5-year OS compared with intensive chemotherapy alone (p = 0.25). Conversely, allo-HSCT significantly improved 5-year OS in non-CR1 patients (p < 0.001). Notably, HLA-matched HSCT and haploidentical HSCT showed comparable outcomes in terms of OS, disease-free survival, and cumulative incidence of relapse. In conclusion, allo-HSCT improved outcomes for MS patients within 36 months of disease onset, and haploidentical HSCT emerged as a viable treatment option for patients without matched donors.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High level serum IL-6 predicts occurrence of TA-TMA. 高水平的血清 IL-6 可预测 TA-TMA 的发生。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-11-27 DOI: 10.1038/s41409-024-02478-x
Renzhi Zheng, Lin Li, Jianzhi Zhao, Diange Jin, Jimin Shi, Yanmin Zhao, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Congxiao Zhang, Jia Shen, He Huang, Yi Luo, Yishan Ye
{"title":"High level serum IL-6 predicts occurrence of TA-TMA.","authors":"Renzhi Zheng, Lin Li, Jianzhi Zhao, Diange Jin, Jimin Shi, Yanmin Zhao, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Congxiao Zhang, Jia Shen, He Huang, Yi Luo, Yishan Ye","doi":"10.1038/s41409-024-02478-x","DOIUrl":"https://doi.org/10.1038/s41409-024-02478-x","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142738257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study. 用于预测接受异体造血干细胞移植的 CMML 患者早期复发的多因素风险评分系统:一项具有全国代表性的多中心研究。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-11-25 DOI: 10.1038/s41409-024-02480-3
Jian-Ying Zhou, Yu-Xiu Chen, Hai-Long Yuan, Ya-Jing Xu, Xiao-Bing Huang, Su-Jun Gao, Yi-Cheng Zhang, Fang Zhou, Xian-Min Song, Yi Luo, Jian-Min Yang, Yu-Hua Li, Shun-Qing Wang, Yu-Jun Dong, Xi Zhang, Yi-Mei Feng, Xin Du, Han Zhu, Zun-Min Zhu, Ke-Hong Bi, Ming Jiang, Ting Niu, Ding-Ming Wan, Yi Chen, Li Liu, Hai Yi, Yu-Hong Chen, Feng-Rong Wang, Yuan-Yuan Zhang, Xiao-Dong Mo, Wei Han, Jing-Zhi Wang, Yu Wang, Huan Chen, Xiang-Yu Zhao, Ying-Jun Chang, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Hui Zhang
{"title":"A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study.","authors":"Jian-Ying Zhou, Yu-Xiu Chen, Hai-Long Yuan, Ya-Jing Xu, Xiao-Bing Huang, Su-Jun Gao, Yi-Cheng Zhang, Fang Zhou, Xian-Min Song, Yi Luo, Jian-Min Yang, Yu-Hua Li, Shun-Qing Wang, Yu-Jun Dong, Xi Zhang, Yi-Mei Feng, Xin Du, Han Zhu, Zun-Min Zhu, Ke-Hong Bi, Ming Jiang, Ting Niu, Ding-Ming Wan, Yi Chen, Li Liu, Hai Yi, Yu-Hong Chen, Feng-Rong Wang, Yuan-Yuan Zhang, Xiao-Dong Mo, Wei Han, Jing-Zhi Wang, Yu Wang, Huan Chen, Xiang-Yu Zhao, Ying-Jun Chang, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Hui Zhang","doi":"10.1038/s41409-024-02480-3","DOIUrl":"https://doi.org/10.1038/s41409-024-02480-3","url":null,"abstract":"<p><p>Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy and the only curable therapy is allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, allo-HSCT is not appropriate for all CMML patients, and relapse is the leading cause of treatment failure. This project conducted a nationwide multicenter real-world study to develop a novel prediction scoring system for early relapse. A total of 238 CMML patients from twenty-seven medical centers treated with allo-HSCT, and 307 adult patients with CMML who underwent allo-HSCT in a publicly available research dataset from the Center for International Blood and Marrow Transplantation Registry (CIBMTR) database were included. Independent prognostic factors for the early relapse of CMML posttransplantation were identified according to competing risk regression methods. Four prognostic factors were identified: bone marrow blasts >10% (hazard ratio [HR], 4.262; P = 0.014), age >60 years (HR, 6.221; P = 0.007), hemoglobin level <100 g/L (HR, 3.695; P = 0.004), and non TET2 gene mutation (HR, 3.425; P = 0.017). A risk-grading scoring system was developed based on the regression coefficients and patients were stratified into low-risk (0-1 point), intermediate-risk (1.5-2 points) and high-risk ( > 2 points) groups. The validated internal c-statistic was 0.767 (95% confidence interval [CI], 0.674-0.860), and the external c-statistic was 0.769 (95% CI, 0.703-0.836). In the derivation cohort, the cumulative incidence rates of early relapse in the low-risk, intermediate-risk, and high-risk groups were 1.35% (95% CI: 1-4%), 10.40% (95% CI: 4-16%), and 29.54% (95% CI: 16-39%) (P < 0.001), respectively. This scoring system can be utilized to early identification of patients at a high risk of relapse and contributing to the implementation of urgent medical support.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信